Diagnosis、treatment、and screening of Barrett's esophagus

doi:10.3877/cma.j.issn.2095-8765.2018.03.008

Abstract

Abstract:

In recent years, both in China and western countries, the incidence of Barrett's esophagus is on the rise, As the only known precancerous lesion of esophageal adenocarcinoma, the diagnosis and screening of Barrett's esophagus have a very important role in the prevention and treatment of esophageal adenocarcinoma. This article reviews the latest advances in the definition、diagnosis、treatment、and screening of Barrett's esophagus.

Key words: Barrett's esophagus, Esophageal adenocarcinoma, Diagnosis, Therapy, Screening

Tian Jin, Xiaoyun Yu. Diagnosis、treatment、and screening of Barrett's esophagus[J]. Chinese Journal of Gastroesophageal Reflux Disease(Electronic Edition), 2018, 05(03): 125-129.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhwsgflbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8765.2018.03.008

https://zhwsgflbdzzz.cma-cmc.com.cn/EN/Y2018/V05/I03/125

References 34

[1]	马丹，杨帆，廖专，等．中国早期食管癌筛查及内镜诊治专家共识意见（2014年，北京）[J]．胃肠病学, 2015(4):220-240.
[2]	Shiota S, Singh S, Anshasi A, et al. Prevalence of Barrett's Esophagus in Asian Countries: A Systematic Review and Meta-analysis[J]. Clin Gastroenterol Hepatol, 2015, 13(11):1907-1918.
[3]	Sharma P, Dent J, Armstrong D, et al. The Development and Validation of an Endoscopic Grading System for Barrett's Esophagus:The Prague C&M Criteria [J]. Gastroenterology, 2006,131(5):1392-1399.
[4]	Kinjo T, Kusano C, Oda I, et al. Prague C&M and Japanese criteria: shades of Barrett's esophagus endoscopic diagnosis [J]. J Gastroenterol, 2010,45(10):1039-1044.
[5]	Shaheen NJ, Falk GW, Iyer PG, et al. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus[J]. Am J Gastroenterol, 2016,111(1):30-50, 51.
[6]	李鹏，王拥军，陈光勇，等．中国巴雷特食管及其早期腺癌筛查与诊治共识（2017万宁) [J]．中国实用内科杂志, 2017(09):798-809.
[7]	房殿春，林三仁，于中麟，等. Barrett食管诊治共识（修订版2011年6月重庆）[J]．胃肠病学, 2011(08):485-486.
[8]	Harrison R, Perry I, Haddadin W, et al. Detection of Intestinal Metaplasia in Barrett's Esophagus: An Observational Comparator Study Suggests the Need for a Minimum of Eight Biopsies [J]. Am J of Gastroenterol, 2007, 102(6):1154-1161.
[9]	Naini BV, Chak A, Ali MA, et al. Barrett's oesophagus diagnostic criteria: endoscopy and histology [J]. Best Practice Res Clin Gastroenterol, 2015, 29(1):77-96.
[10]	Bandla S, Peters JH, Ruff D, et al. Comparison of Cancer-Associated Genetic Abnormalities in Columnar-Lined Esophagus Tissues With and Without Goblet Cells [J]. Ann Surg, 2014, 260(1):72-80.
[11]	Lavery DL, Martinez P, Gay LJ, et al. Evolution of oesophageal adenocarcinoma from metaplastic columnar epithelium without goblet cells in Barrett's oesophagus [J]. Gut, 2016,65(6):907-913.
[12]	Tan WK, di Pietro M, Fitzgerald RC. Past, present and future of Barrett's oesophagus [J]. Eur J of Surg Oncol, 2017,43(7):1148-1160.
[13]	Falk GW, Rice TW, Goldblum JR, et al. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia [J]. Gastrointestinal Endosc, 1999, 49(2):170-176.
[14]	Sharma P, Hawes RH, Bansal A, et al. Standard endoscopy with random biopsies versus narrow band imaging targeted biopsies in Barrett's oesophagus: a prospective, international, randomised controlled trial [J]. Gut, 2012, 62(1):15-21.
[15]	Ngamruengphong S, Sharma VK, Das A. Diagnostic yield of methylene blue chromoendoscopy for detecting specialized intestinal metaplasia and dysplasia in Barrett's esophagus: a meta-analysis [J]. Gastrointest Endosc, 2009, 69(6):1021-1028.
[16]	Tholoor S, Bhattacharyya R, Tsagkournis O, et al. Acetic acid chromoendoscopy in Barrett's esophagus surveillance is superior to the standardized random biopsy protocol: results from a large cohort study (with video) [J]. Gastrointest Endosc, 2014, 80(3):417-424.
[17]	Sturm MB, Wang TD. Emerging optical methods for surveillance of Barrett's oesophagus [J]. Gut, 2015, 64(11):1816-1823.
[18]	Cobb MJ, Hwang JH, Upton MP, et al. Imaging of subsquamous Barrett's epithelium with ultrahigh-resolution optical coherence tomography: a histologic correlation study [J]. Gastrointestinal Endosc, 2010, 71(2):223-230.
[19]	Evans JA, Poneros JM, Bouma BE, et al. Optical coherence tomography to identify intramucosal carcinoma and high-grade dysplasia in Barrett's esophagus[J]. Clin Gastroenterol Hepatol, 2006, 4(1):38-43.
[20]	Swager AF, Boerwinkel DF, de Bruin DM, et al. Detection of buried Barrett's glands after radiofrequency ablation with volumetric laser endomicroscopy [J]. Gastrointest Endosc, 2016, 83(1):80-88.
[21]	di Pietro M, Boerwinkel DF, Shariff MK, et al. The combination of autofluorescence endoscopy and molecular biomarkers is a novel diagnostic tool for dysplasia in Barrett's oesophagus [J]. Gut, 2015, 64(1):49-56.
[22]	Spechler SJ. Barrett esophagus and risk of esophageal cancer: a clinical review [J]. JAMA, 2013, 310(6):627-636.
[23]	Gorospe EC, Wang KK. Risk stratification and surveillance in Barrett oesophagus [J]. Nature Re Gastroenterol Hepatol, 2014, 11(2):82-84.
[24]	Kastelein F, Biermann K, Steyerberg EW, et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus [J]. Gut, 2013, 62(12):1676-1683.
[25]	Wani S, Rubenstein JH, Vieth M, et al. Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association [J]. Gastroenterology, 2016, 151(5):822-835.
[26]	Duits LC, van der Wel MJ, Cotton CC, et al. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia [J]. Gastroenterology, 2017, 152(5):993-1001.
[27]	Sami SS, Ragunath K, Iyer PG. Screening for Barrett's Esophagus and Esophageal Adenocarcinoma: Rationale, Recent Progress, Challenges, and Future Directions [J]. Clin Gastroenterol Hepatol, 2015, 13(4):623-634.
[28]	Ross-Innes CS, Debiram-Beecham I, O'Donovan M, et al. Evaluation of a Minimally Invasive Cell Sampling Device Coupled with Assessment of Trefoil Factor 3 Expression for Diagnosing Barrett's Esophagus: A Multi-Center Case-Control Study [J]. PLOS Medicine, 2015,12(1):e1001780.
[29]	Kastelein F, Spaander MCW, Steyerberg EW, et al. Proton Pump Inhibitors Reduce the Risk of Neoplastic Progression in Patients With Barrett's Esophagus [J]. Clin Gastroenterol Hepatol, 2013, 11(4):382-388.
[30]	Kastelein F, Spaander MCW, Biermann K, et al. Nonsteroidal Anti- Inflammatory Drugs and Statins Have Chemopreventative Effects in Patients With Barrett's Esophagus [J]. Gastroenterology, 2011, 141(6):2000-2008.
[31]	Konda VJ, Gonzalez HRM, Koons A, et al. Complete endoscopic mucosal resection is effective and durable treatment for Barrett's-associated neoplasia [J]. Clin Gastroenterol Hepatol, 2014, 12(12):2002-2010.
[32]	Terheggen G, Horn EM, Vieth M, et al. A randomised trial of endoscopic submucosal dissection versus endoscopic mucosal resection for early Barrett's neoplasia [J]. Gut, 2017, 66(5):783-793.
[33]	Orman ES, Li N, Shaheen NJ. Efficacy and Durability of Radiofrequency Ablation for Barrett's Esophagus: Systematic Review and Meta-analysis [J]. Clin Gastroenterol Hepatol, 2013, 11(10):1245-1255.
[34]	Canto M, Shin E, Khashab M, et al. Safety and efficacy of carbon dioxide cryotherapy for treatment of neoplastic Barrett's esophagus[J]. Endoscopy, 2015, 47(7):591.

Please choose a citation manager

Content to export